妖姬直播

Pulmonology >

Cystic Fibrosis

News, opinions and meeting coverage in pulmonology.

PDE3/4 Inhibitor Yields Symptom Relief in COPD

Tested as standalone, but potential role seen as add-on therapy

Asthma Biologic, Rally Among ATS Highlights

Attendees to organize on Capitol Hill; will also hear benralizumab phase III results

Gross Anatomy: Breast Implant Makes a Break for It

Interthoracic migration not unheard of

Kalydeco: A Price Too High to Pay?

A 妖姬直播/Milwaukee Journal Sentinel report revealed the staggering annual treatment cost for the cystic fibrosis drug ivacaftor (Kalydeco) as part of an investigation of venture philanthrophy -- now a JAMA Viewpoint echoes those findings.

Cystic Fibrosis: Charity and Industry Partner for Profit

When a disease-related charity becomes a venture capitalist, count the pharmaceutical industry among the winners, but the charity is not far behind as John Fauber explains in this Milwaukee Journal Sentinel/妖姬直播 investigation.

Denufosol Improves Airway Function in Cystic Fibrosis

DURHAM, N.C. -- The investigational cystic fibrosis drug denufosol significantly improved large airway function in a randomized placebo-controlled phase III trial, drugmaker Inspire Pharmaceuticals announced today.

CF Death Prompts FDA Alert on Nebulized Liquid Colisthemethate

ROCKVILLE, Md. -- The death of cystic fibrosis patient had led the FDA to alert physicians about the risk of prescribing premixed colistimethate for inhalation with a nebulizer.